- Home
- HRMY vs PACS Comparison
HRMY vs PACS Comparison
Compare HRMY & PACS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- PACS
- Stock Information
- Founded
- HRMY 2017
- PACS 2013
- Country
- HRMY United States
- PACS United States
- Employees
- HRMY N/A
- PACS N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- PACS
- Sector
- HRMY Health Care
- PACS
- Exchange
- HRMY Nasdaq
- PACS Nasdaq
- Market Cap
- HRMY 1.8B
- PACS 2.0B
- IPO Year
- HRMY 2020
- PACS 2024
- Fundamental
- Price
- HRMY $34.00
- PACS $12.72
- Analyst Decision
- HRMY Strong Buy
- PACS Strong Buy
- Analyst Count
- HRMY 9
- PACS 7
- Target Price
- HRMY $54.44
- PACS $34.29
- AVG Volume (30 Days)
- HRMY 642.5K
- PACS 791.9K
- Earning Date
- HRMY 08-05-2025
- PACS 08-11-2025
- Dividend Yield
- HRMY N/A
- PACS N/A
- EPS Growth
- HRMY 13.13
- PACS 82.80
- EPS
- HRMY 2.62
- PACS 0.68
- Revenue
- HRMY $744,852,000.00
- PACS $3,558,953,000.00
- Revenue This Year
- HRMY $20.10
- PACS $29.74
- Revenue Next Year
- HRMY $18.01
- PACS $14.22
- P/E Ratio
- HRMY $13.10
- PACS $18.56
- Revenue Growth
- HRMY 20.62
- PACS 205.08
- 52 Week Low
- HRMY $26.47
- PACS $8.28
- 52 Week High
- HRMY $41.61
- PACS $43.92
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- PACS N/A
- Support Level
- HRMY $31.70
- PACS N/A
- Resistance Level
- HRMY $35.08
- PACS N/A
- Average True Range (ATR)
- HRMY 0.95
- PACS 0.00
- MACD
- HRMY 0.27
- PACS 0.00
- Stochastic Oscillator
- HRMY 71.80
- PACS 0.00
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About PACS PACS Group Inc. Common Stock
PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.